Macromolecules as taxane delivery systems

Expert Opinion on Drug Delivery

Volumn 8, Issue 1, 2011, Pages 33-55

  Dosio, Franco ^a   Stella, Barbara ^a   Arpicco, Silvia ^a   Cattel, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Anticancer agents; Macromolecules; Paclitaxel; Polymers; Polysaccharides; Taxanes

Indexed keywords

3' TERT BUTYL 3' N TERT BUTYLOXYCARBONYL 4 DEACETYL 3' N DEBENZOYL 3' DEPHENYL 4 O METHOXYCARBONYLPACLITAXEL; ABI 008; ALBUMIN; AZ10992; BASIC FIBROBLAST GROWTH FACTOR; CARBOPLATIN; CARBOXYMETHYLDEXTRAN; CHITOSAN; DENDRIMER; DOCETAXEL; DOXORUBICIN; ESTRADIOL; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; HEPARIN; HYALURONIC ACID; MACROGOL; MONOCLONAL ANTIBODY; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NAVELBINE; NKTR 105; OPAXIO; PACLITAXEL; PACLITAXEL POLIGLUMEX; PACLITAXEL TOCOSOL; PNU 166945; POLYGLUTAMIC ACID; TAXOPREXIN; TOCOSOL; TRANSFERRIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ALOPECIA; BINDING AFFINITY; BLOOD TOXICITY; BREAST CANCER; COVALENT BOND; CROSS COUPLING REACTION; DNA BINDING; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SOLUBILITY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; MACROMOLECULE; METASTASIS; MICELLE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERIZATION; PRIMARY TUMOR; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; POLYMERS; POLYSACCHARIDES; PROTEINS; SOLUBILITY; TAXOIDS;

EID: 78650581657     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.541437     Document Type: Review

References (179)

1. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: Optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 2010;7(1):22-36
2. Simpson D, Plosker GL. Paclitaxel: As adjuvant or neoadjuvant therapy in early breast cancer. Drugs 2004;64(16):1839-47 (Pubitemid 39215192)
3. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001;15(3):525-45 (Pubitemid 32762172)
4. Rowinsky EK, Calvo E. Novel agents that target tubulin and related elements. Semin Oncol 2006;33(4):421-35 (Pubitemid 44142739)
5. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356(10):998-1008 (Pubitemid 46376800)
6. Tiroch KA, Byrne RA, Kastrati A. Pharmacological prevention and management of restenosis. Expert Opin Pharmacother 2010;11(11):1855-72
7. Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: An overview of the pharmacokinetics and pharmacodynamics. Urology 1999;54(6 Suppl 1):22-9
8. Bhutani M, Colucci PM, Laird-Fick H, Conley BA. Management of paclitaxel-induced neurotoxicity. Oncol Rev 2010;4(2):107-15
9. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8(7):1263-8
10. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere(TM)). Ann Oncol 1993;4(7):610-1 (Pubitemid 23257562)
11. Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001;28(4 Suppl 15):62-6 (Pubitemid 32947554)
12. Marupudi NI, Han JE, Li KW, et al. Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007;6(5):609-21 . An exhaustive review on taxanes' side effects.
13. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: Molecular mechanisms and development of new generation taxanes. ChemMedChem 2007;2(7):920-42
14. Ferlini C, Gallo D, Scambia G. New taxanes in development. Expert Opin Investig Drugs 2008;17(3):335-47 (Pubitemid 351578186)
15. Elstad NL, Fowers KD. OncoGel (ReGel/paclitaxel) -Clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 2009;61(10):785-94
16. Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;108(2):241-50
17. Berlin JM, Leonard AD, Pham TT, et al. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified paclitaxel. ACS Nano 2010;4(8):4621-36
18. Tong R, Cheng JJ. Anticancer polymeric nanomedicines. Polym Rev 2007;47(3):345-81 (Pubitemid 47240845)
19. Singh S, Dash AK. Paclitaxel in cancer treatment: Perspectives and prospects of its delivery challenges. Crit Rev Ther Drug Carrier Syst 2009;26(4):333-72 . An excellent review on recent development of taxane delivery systems.
20. Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47(10):2393-404 (Pubitemid 38580074)
21. Kingston DGI, Jagtap PG, Yuan H, Samala L. The chemistry of taxol and related taxoids. Fortschr Chem Org Naturst 2002;84:53-225
22. Skwarczynski M, Hayashi Y, Kiso Y. Paclitaxel prodrugs: Toward smarter delivery of anticancer agents. J Med Chem 2006;49(25):7253-69 (Pubitemid 44913386)
23. Greish K, Fang J, Inutsuka T, et al. Macromolecular therapeutics: Advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003;42(13):1089-105 (Pubitemid 37357647)
24. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug Chem 2010;21(5):797-802 . A more recent overview on the EPR effect with interesting perspectives such as NO donors' role.
25. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987;6(4):559-93
26. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997;57(4):765-72
27. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296(5574):1883-6 (Pubitemid 34596277)
28. Leu AJ, Berk DA, Lymboussaki A, et al. Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. Cancer Res 2000;60(16):4324-7 (Pubitemid 32103603)
29. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7(11):653-64 . A more recent and important review on nanomedicine and tumor penetration with particular focus on barrier, vasculature and the EPR effect.
30. Takakura Y, Hashida M. Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution. Pharm Res 1996;13(6):820-31 (Pubitemid 26227738)
31. Cheng Y, Xu T. The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs. Eur J Med Chem 2008;43(11):2291-7
32. Ulbrich K, Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev 2004;56(7):1023-50 (Pubitemid 38520207)
33. de Groot FMH, Damen EWP, Scheeren HW. Anticancer prodrugs for application in monotherapy: Targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem 2001;8(9):1093-122
34. Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 2008;15(18):1802-26
35. Damen EWP, Nevalainen TJ, van den Bergh TJM, et al. Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue. Bioorg Med Chem 2002;10(1):71-7
36. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6(9):688-701 (Pubitemid 44286001)
37. Neerman MF. Enhancing the site-specific targeting of macromolecular anticancer drug delivery systems. Curr Drug Targets 2006;7(2):229-35
38. Bolling C, Graefe T, Lubbing C, et al. Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest New Drugs 2006;24(6):521-7 (Pubitemid 44273028)
39. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2- hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents -Drug-polymer conjugates. Clin Cancer Res 1999;5(1):83-94 (Pubitemid 29045181)
40. Venditto VJ, Simanek EE. Cancer therapies utilizing the camptothecins: A review of the in vivo literature. Mol Pharm 2010;7(2):307-49
41. Rademaker-Lakhai JM, Terret C, Howell SB, et al. A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004;10(10):3386-95 (Pubitemid 38685444)
42. Fossella F, McCann J, Tolcher A, et al. Phase II trial of BB-10901 (huN901- DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma. J Clin Oncol 2005;23(16):660S-S
43. Voutsadakis IA. Gemtuzumab ozogamicin (CMA-676, Mylotarg) for the treatment of CD33(+) acute myeloid leukemia. Anti Cancer Drugs 2002;13(7):685-92
44. Malingre MM, Beijnen JH, Schellens JHM. Oral delivery of taxanes. Invest New Drugs 2001;19(2):155-62
45. Broker LE, Veltkamp SA, Heath EI, et al. A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res 2007;13(13):3906-12
46. Nicoletti MI, Colombo T, Rossi C, et al. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res 2000;60(4):842-6 (Pubitemid 30129512)
47. Sampath D, Discafani CM, Loganzo F, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2003;2(9):873-84
48. Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophor (R) EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 2005;59(1):177-87 (Pubitemid 39573451)
49. Fetterly GJ, Grasela TH, Sherman JW, et al. Pharmacokinetic/ pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res 2008;14(18):5856-63
50. Constantinides PP, Tustian A, Kessler DR. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev 2004;56(9):1243-55 (Pubitemid 38510472)
51. Bulitta JB, Zhao P, Arnold RD, et al. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 2009;63(6):1035-48
52. Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001;7(10):3229-38
53. Kuznetsova L, Chen J, Sun L, et al. Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett 2006;16(4):974-7 (Pubitemid 43059863)
54. Homsi J, Bedikian AY, Kim KB, et al. Phase II open-label study of weekly taxoprexin (TXP) as first-line treatment in patients with metastatic cutaneous and mucosal malignant melanoma. Meeting Abstracts. J Clin Oncol 2008;26(15 Suppl):9056
55. Fracasso PM, Picus J, Wildi JD, et al. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin(A (R)), in resistant solid tumor malignancies. Cancer Chemother Pharmacol 2009;63(3):451-8
56. Fu Q, Sun J, Zhang WP, et al. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Rec Pat Anti Cancer Drug Discov 2009;4(3):262-72
57. Roy V, Laplant BR, Gross GG, et al. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nabpaclitaxel) (AbraxaneA®) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20(3):449-53
58. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12(4):1317-24 (Pubitemid 43342524)
59. Damascelli B, Cantu G, Mattavelli F, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007) -Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: Preliminary evidence of clinical activity. Cancer 2001;92(10):2592-602 (Pubitemid 33049443)
60. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: An overview. Adv Drug Deliv Rev 2009;61(13):1177-88
61. Li C, Yu D, Inoue T, et al. Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anti Cancer Drugs 1996;7(6):642-8 (Pubitemid 26348842)
62. Deutsch HM, Glinski JA, Hernandez M, et al. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. J Med Chem 1989;32(4):788-92 (Pubitemid 19100192)
63. Greenwald RB, Gilbert CW, Pendri A, et al. Drug delivery systems: Water soluble taxol 2'-Poly(ethylene glycol) ester prodrugs design and in vivo effectiveness. J Med Chem 1996;39:424-31 (Pubitemid 26037894)
64. Greenwald RB, Pendri A, Bolikal D, Gilbert CW. Highly water-soluble taxol derivatives -2'-polyethyleneglycol esters as potential prodrugs. Bioorg Med Chem Lett 1994;4(20):2465-70 (Pubitemid 24324561)
65. Feng X, Yuan YJ, Wu JC. Synthesis and evaluation of water-soluble paclitaxel prodrugs. Bioorg Med Chem Lett 2002;12(22):3301-3 (Pubitemid 35248235)
66. Rodrigues PCA, Scheuermann K, Stockmar C, et al. Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg Med Chem Lett 2003;13(3):355-60 (Pubitemid 36259691)
67. Schoenmakers RG, Van De Wetering P, Elbert DL, Hubbell JA. The effect of the linker on the hydrolysis rate of drug-linked ester bonds. J Control Release 2004;95(2):291-300 (Pubitemid 38230043)
68. Hess M, Jo BW, Wermeckes B, et al. Properties of a water-soluble paclitaxel conjugate in aqueous solution and its interaction with serum albumin. Macromol Symp 2006;231:28-46 (Pubitemid 43207130)
69. Choi JS, Jo BW. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm 2004;280(1-2):221-7
70. Beeram MREK, Hammond LA, Patnaik A, et al. A phase I and pharmacokinetic (PK) study of PEG-paclitaxel in patients with advanced solid tumors. ASCO Annual Meeting 2002; 2002. p. 405
71. Enzon annual report 2003. Available from: Http://investor.enzon.com/ downloads/ENZON2003AR.pdf [Cited] [Last accessed 30 September 2010]
72. Safavy A, Raisch KP, Khazaeli MB, et al. Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes. J Med Chem 1999;42(23):4919-24
73. Safavy A, Raisch KP, Matusiak D, et al. Single-drug multiligand conjugates: Synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide 'scorpion' molecule. Bioconjug Chem 2006;17(3):565-70 (Pubitemid 43794364)
74. Wolff R, Routt S, Hartsook R, et al. NKTR-105, a novel PEGylated-docetaxel demonstrates superior anti-tumor activity compared to docetaxel in human non-samll cell lung and colon cancer xenografts. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2008; Geneva, Switzerland; 2008. p. 448
75. Kozlowski A. A method is provided for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid or ester thereof. US7569214B2, 2009
76. Liu J, Zahedi P, Zeng F, Allen C. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J Pharm Sci 2008;97(8):3274-90
77. Gale S, Croasdell G. 28th Annual JPMorgan Healthcare Conference Exelixis and Nektar Therapeutics 11-14 January 2010, San Francisco, CA, USA. IDrugs 2010;13(3):139-41
78. Mccormick-Thomson LA, Duncan R. Poly(amino acid) copolymers as a potential soluble drug delivery system. 1. Pinocytic uptake and lysosomal degradation measured in vitro. J Bioactive Compatible Polym 1989;4(3):242-51 (Pubitemid 19230140)
79. Mccormick-Thomson LA, Sgouras D, Duncan R. Poly(amino acid) copolymers as a potential soluble drug delivery system. 2. Body distribution and preliminary biocompatibility testing in vitro and in vivo. J Bioactive Compatible Polym 1989;4(3):252-68 (Pubitemid 19230140)
80. Li C. Poly(-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev 2002;54(5):695-713 A relevant review on Polyglumex.
81. Kishore BK, Lambricht P, Laurent G, et al. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids. J Pharmacol Exp Ther 1990;255(2):875-85
82. Langer CJ. CT-2103: Emerging utility and therapy for solid tumours. Expert Opin Investig Drugs 2004;13(11):1501-8
83. Singer JW. Paclitaxel poliglumex (XYOTAX(TM), CT-2103): A macromolecular taxane. J Control Release 2005;109(1-3):120-6
84. Shaffer SA, Baker-Lee C, Kennedy J, et al. In vitro and in vivo metabolism of paclitaxel poliglumex: Identification of metabolites and active proteases. Cancer Chemother Pharmacol 2007;59(4):537-48 (Pubitemid 46122332)
85. Podgorski I, Sloane BF. Cathepsin B and its role(s) in cancer progression. In: Saklatvala J, Nagase H, Salvesen G, editors, Proteases and the regulation of biological processes. Portland Press Ltd, London; 2003. p. 263-76 (Pubitemid 38497232)
86. Auzenne E, Donato NJ, Li C, et al. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with Taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res 2002;8(2):573-81 (Pubitemid 34193979)
87. Li C, Yu DF, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly (L-glutamic acid) paclitaxel conjugate. Cancer Res 1998;58(11):2404-9 (Pubitemid 28252701)
88. Mita M, Mita A, Sarantopoulos J, et al. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemother Pharmacol 2009;64(2):287-95
89. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006;42(1):24-30 (Pubitemid 41814529)
90. Boddy AV, Plummer ER, Todd R, et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 2005;11(21):7834-40 (Pubitemid 41611628)
91. Sabbatini P, Sill MW, O'Malley D, et al. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study. Gynecol Oncol 2008;111(3):455-60
92. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008;98(10):1608-13 (Pubitemid 351684693)
93. O'Brien MER, Socinski MA, Popovich AY, et al. Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008;3(7):728-34
94. Langer CJ, O'Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008;3(6):623-30
95. Dipetrillo T, Milas L, Evans D, et al. Paclitaxel poliglumex (PPX-xyotax) and concurrent radiation for esophageal and gastric cancer -A phase I study. Am J Clin Oncol Cancer Clin Trials 2006;29(4):376-9 (Pubitemid 44197542)
96. Beer TM, Ryan C, Alumkal J, et al. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anti Cancer Drugs 2010;21(4):433-8
97. Fontaine TN, Suntharalingam JM, Dipetrillo T, et al. Neoadjuvant paclitaxel poliglumex (PPX), cisplatin, and radiation (RT) for esophageal cancer. J Clin Oncol 2010;28(15s):4085
98. Wang XH, Zhao G, Van S, et al. Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol 2010;65(3):515-26
99. Feng ZL, Zhao G, Yu L, et al. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol 2010;65(5):923-30
100. Zhang S-Q, Song Y-N, He X-H, et al. Liquid chromatography-tandem mass spectrometry for the determination of paclitaxel in rat plasma after intravenous administration of poly(L-glutamic acid)-alanine-paclitaxel conjugate. J Pharm Biomed Anal 2009;51(5):1169-74
101. Cavallaro G, Licciardi M, Caliceti P, et al. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. Eur J Pharm Biopharm 2004;58(1):151-9 (Pubitemid 38781016)
102. Cavallaro G, Maniscalco L, Campisi M, et al. Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety. Eur J Pharm Biopharm 2007;66(2):182-92 (Pubitemid 46654771)
103. Kopecek J, Kopeckova P. HPMA copolymers: Origins, early developments, present, and future. Adv Drug Deliv Rev 2010;62(2):122-49
104. Ulbrich K, Subr V. Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev 2010;62(2):150-66
105. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20(6):1668-76 (Pubitemid 34260549)
106. Lammers T, Subr V, Ulbrich K, et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 2009;30(20):3466-75
107. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti Cancer Drugs 2001;12(4):315-23
108. Duncan R. Development of HPMA copolymer-anticancer conjugates: Clinical experience and lessons learnt. Adv Drug Deliv Rev 2009;61(13):1131-48 . A very important commentary on HPMA and uses as drug delivery systems.
109. Etrych T, Sirova M, Starovoytova L, et al. HPMA copolymer conjugates of paclitaxel and docetaxel with ph-controlled drug release. Mol Pharm 2010;7(4):1015-26
110. Duncan R, Vicent MJ. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev 2010;62(2):272-82
111. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discov Today 2010;15(5-6):171-85
112. de Groot FM, Albrecht C, Koekkoek R, et al. 'Cascade-release dendrimers' liberate all end groups upon a single triggering event in the dendritic core. Angew Chem Int Ed Engl 2003;42(37):4490-4 (Pubitemid 37214521)
113. Erez R, Segal E, Miller K, et al. Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel. Bioorg Med Chem 2009;17(13):4327-35
114. Majoros IJ, Myc A, Thomas T, et al. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality. Biomacromolecules 2006;7(2):572-9 (Pubitemid 43309153)
115. Bi X, Shi X, Majoros IJ, et al. Multifunctional poly(amidoamine) dendrimer-taxol conjugates: Synthesis, characterization and stability. J Comput Theor Nanosci 2007;4(6):1179-87 (Pubitemid 350148576)
116. Khandare JJ, Jayant S, Singh A, et al. Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug Chem 2006;17(6):1464-72 (Pubitemid 44851491)
117. Saad M, Garbuzenko OB, Ber E, et al. Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 2008;130(2):107-14 An interesting comparison of different targeted carriers loaded with PTX.
118. Minko T, Patil ML, Zhang M, et al. LHRH-targeted nanoparticles for cancer therapeutics. Methods Mol Biol 2010:624:281-94
119. Lim J, Simanek EE. Synthesis of water-soluble dendrimers based on melamine bearing 16 paclitaxel groups. Org Lett 2008;10(2):201-4
120. Simanek EE, Abdou H, Lalwani S, et al. The 8 year thicket of triazine dendrimers: Strategies, targets and applications. Proc R Soc Math Phys Eng Sci 2010;466(2117):1445-68
121. Lo ST, Stern S, Clogston JD, et al. Biological assessment of triazine dendrimer: Toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct. Mol Pharm 2010;7(4):993-1006
122. Lim J, Chouai A, Lo ST, et al. Design, synthesis, characterization, and biological evaluation of triazine dendrimers bearing paclitaxel using ester and ester/disulfide linkages. Bioconjug Chem 2009;20(11):2154-61
123. Benito JM, Gomez-Garcia M, Ortiz Mellet C, et al. Optimizing saccharide-directed molecular delivery to biological receptors: Design, synthesis, and biological evaluation of glycodendrimer-cyclodextrin conjugates. J Am Chem Soc 2004;126(33):10355-63 (Pubitemid 39100790)
124. Harenberg J, Casu B. Heparin and its derivatives -Present and future. Thromb Haemost 2009;102(5):801-3
125. Soker S, Goldstaub D, Svahn CM, et al. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. Biochem Biophys Res Commun 1994;203(2):1339-47 (Pubitemid 24304976)
126. Jayson GC, Gallagher JT. Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997;75(1):9-16
127. Lapierre F, Holme K, Lam L, et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 1996;6(3):355-66 (Pubitemid 26160105)
128. Naggi A, Casu B, Perez M, et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 2005;280(13):12103-13 (Pubitemid 40491020)
129. Park IK, Kim YJ, Tran TH, et al. Water-soluble heparin-PTX conjugates for cancer targeting. Polymer 2010;51(15):3387-93
130. Wang Y, Xin D, Liu K, Xiang J. Heparin-Paclitaxel conjugates using mixed anhydride as intermediate: Synthesis, influence of polymer structure on drug release, anticoagulant activity and in vitro efficiency. Pharm Res 2009;26(4):785-93
131. Wang Y, Xin D, Liu K, et al. Heparin-paclitaxel conjugates as drug delivery system: Synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem 2009;20(12):2214-21
132. Dodane V, Vilivalam VD. Pharmaceutical applications of chitosan. Pharm Sci Technol Today 1998;1(6):246-53 (Pubitemid 28439296)
133. Kumar MNVR, Muzzarelli RAA, Muzzarelli C, et al. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 2004;104(12):6017-84 (Pubitemid 40025733)
134. Chae SY, Jang MK, Nah JW. Influence of molecular weight on oral absorption of water soluble chitosans. J Control Release 2005;102(2):383-94
135. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev 2010;62(1):28-41
136. Lee E, Lee J, Lee IH, et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008;51(20):6442-9
137. Lee E, Kim H, Lee IH, Jon S. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release 2009;140(2):79-85
138. Entwistle J, Hall CL, Turley EA. HA receptors: Regulators of signalling to the cytoskeleton. J Cell Biochem 1996;61(4):569-77 (Pubitemid 26240134)
139. Stern R. Association between cancer and 'acid mucopolysaccharides': An old concept comes of age, finally. Semin Cancer Biol 2008;18(4):238-43
140. Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 1999;10(5):755-63 (Pubitemid 29456361)
141. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid -Taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000;1(2):208-18
142. Auzenne E, Ghosh SC, Khodadadian M, et al. Hyaluronic acid-paclitaxel: Antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007;9(6):479-86 (Pubitemid 46983450)
143. Xin D, Wang Y, Xiang J. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: Synthesis, self-assembled property, drug release, and in vitro efficiency. Pharm Res 2010;27(2):380-9
144. Nicolaou KCR, Riemerc C, Kerr MA, et al. Design, synthesis and biological activity of protaxols. Nature 1993;364:464-6
145. Paradis R, Page M. New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res 1998;18(4A):2711-16 (Pubitemid 28064867)
146. Magri NF, Kingston DGI. Modified taxols, 4. Synthesis and biological activity of taxols modified in the side chain. J Nat Prod 1988;51(2):298-306
147. Rosato A, Banzato A, De Luca G, et al. HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer{star, open}. Urol Oncol 2006;24(3):207-15
148. Banzato A, Bobisse S, Rondina M, et al. A paclitaxel-hyaluronan bioconjugateTargeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 2008;14(11):3598-606
149. Sugahara SI, Kajiki M, Kuriyama H, Kobayashi TR. Paclitaxel delivery systems: The use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol Pharm Bulletin 2002;25(5):632-41 (Pubitemid 39663261)
150. Sugahara SI, Kajiki M, Kuriyama H, Kobayashi TR. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J Control Release 2007;117(1):40-50 (Pubitemid 46161869)
151. Nakamura J, Nakajima N, Matsumura K, Hyon SH. Water-soluble taxol conjugates with dextran and targets tumor cells by folic acid immobilization. Anticancer Res 2010;30(3):903-10
152. Bicamumpaka C, Page M. In vitro cytotoxicity of paclitaxel-transferrin conjugate on H69 cells. Oncol Rep 1998;5(6):1381-3 (Pubitemid 28474079)
153. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132(3):171-83
154. John TA, Vogel SM, Tiruppathi C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003;284(1):L187-96 (Pubitemid 35471272)
155. Purcell M, Neault JF, Tajmir-Riahi HA. Interaction of taxol with human serum albumin. Biochim Biophys Acta 2000;1478(1):61-8 (Pubitemid 30136139)
156. Cheng H, Liu H, Zhang Y, Zou G. Interaction of the docetaxel with human serum albumin using optical spectroscopy methods. J Luminescence 2009;129(10):1196-203
157. Dosio F, Brusa P, Crosasso P, et al. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J Control Release 1997;47(3):293-304 (Pubitemid 27220212)
158. Dosio F, Arpicco S, Brusa P, et al. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: Preparation, characterization and pharmacokinetics. J Control Release 2001;76(1-2):107-17 (Pubitemid 32786889)
159. Esmaeili F, Dinarvand R, Ghahremani MH, et al. Docetaxel-albumin conjugates: Preparation, in vitro evaluation and biodistribution studies. J Pharm Sci 2009;98(8):2718-30
160. Dosio F, Arpicco S, Stella B, et al. Folate-mediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system. Int J Pharm 2009;382(1-2):117-23
161. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23(9):1073-8
162. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008;9(6):423-30
163. Chen J, Jaracz S, Zhao X, et al. Antibody-cytotoxic agent conjugates for cancer therapy. Expert Opin Drug Deliv 2005;2(5):873-90 (Pubitemid 41488847)
164. Safavy A, Georg GI, Vander Velde D, et al. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjug Chem 2004;15(6):1264-74 (Pubitemid 39552015)
165. Guillemard V, Nedev HN, Berezov A, et al. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol 2005;24(6):350-8 (Pubitemid 40840343)
166. Guillemard V, Saragovi HU. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res 2001;61(2):694-9 (Pubitemid 32140477)
167. Gilbert CW, McGowan EB, Seery GB, et al. Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINNa'c Linker. J Exp Ther Oncol 2003;3(1):27-35
168. Wang X, Zhu J, Zhao P, et al. In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-taxol conjugate on A431 epidermoid carcinoma cells. Cancer Biol Ther 2007;6(6):980-6
169. Ojima I, Geng XD, Wu XY, et al. Tumor-specific novel taxoid-monoclonal antibody conjugates. J Med Chem 2002;45(26):5620-3 (Pubitemid 35453753)
170. Quiles S, Raisch KP, Sanford LL, et al. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Med Chem 2010;53(2):586-94 A report on a new approach using PEG and mAbs for paclitaxel delivery.
171. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14(4):529-37
172. Duncan R, Kopecek J, Lloyd JB. Drug targeting to lysosomes. Biochem Soc Trans 1984;12(6):913-15 (Pubitemid 15167839)
173. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2010; (In Press)
174. Chen J, Chen S, Zhao X, et al. Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J Am Chem Soc 2008;130(49):16778-85
175. Lay CL, Liu HQ, Tan HR, Liu Y. Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graftcarbon nanotubes for potent cancer therapeutics. Nanotechnology 2010;21(6):065101
176. Ji S-R, Liu C, Zhang B, et al. Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta 2010;1806(1):29-35
177. Li Z, Hulderman T, Salmen R, et al. Cardiovascular effects of pulmonary exposure to single-wall carbon nanotubes. Environ Health Perspect 2007;115(3):377-82 (Pubitemid 46554435)
178. Lesch HP, Kaikkonen MU, Pikkarainen JT, Yla-Herttuala S. Avidin-biotin technology in targeted therapy. Expert Opin Drug Deliv 2010;7(5):551-64
179. Rossin R, Verkerk PR, van den Bosch SM, et al. In vivo chemistry for pretargeted tumor imaging in live mice. Angew Chem Int Ed 2010;49(19):3375-8 First report of a new pretargeting approach based on inverse-electron-demand Diels-Alder reaction.